John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRSH
1476
Marsh
MRSH
$92.3B
| $1.5M | ﹤0.01% |
+8,772
| New | +$1.38M |
|
1477
Farmers National Banc Corp
FMNB
$925M
| $1.49M | ﹤0.01% |
87,041
-5,224
| -6% | -$93.1K |
|
|
PSTL
1478
Postal Realty Trust
PSTL
$708M
| $1.48M | ﹤0.01% |
88,179
-35,019
| -28% | -$623K |
|
1479
i3 Verticals
IIIV
$306M
| $1.48M | ﹤0.01% |
53,200
-58,345
| -52% | -$1.44M |
|
1480
Dime Commercial Bancshares
DCOM
$1.78B
| $1.48M | ﹤0.01% |
42,785
-64,894
| -60% | -$2.26M |
|
|
ASCA
1481
DELISTED
A SPAC I Acquisition Corp. Class A Ordinary Share
ASCA
| $1.48M | ﹤0.01% |
+150,000
| New | +$1.48M |
|
1482
QCR Holdings
QCRH
$1.64B
| $1.47M | ﹤0.01% |
26,055
-8,250
| -24% | -$471K |
|
1483
eGain
EGAN
$198M
| $1.47M | ﹤0.01% |
126,801
+617
| +0.5% | +$6.95K |
|
1484
AquaBounty Technologies
AQB
$6.85M
| $1.46M | ﹤0.01% |
38,979
-21,895
| -36% | -$761K |
|
1485
FLEX LNG
FLNG
$1.73B
| $1.45M | ﹤0.01% |
50,741
+14,790
| +41% | +$330K |
|
1486
Ouster
OUST
$2.61B
| $1.44M | ﹤0.01% |
32,089
-30,168
| -48% | -$1.11M |
|
1487
Enterprise Financial Services Corp
EFSC
$2.29B
| $1.44M | ﹤0.01% |
30,490
-9,080
| -23% | -$445K |
|
1488
Anavex Life Sciences
AVXL
$330M
| $1.44M | ﹤0.01% |
+116,833
| New | +$1.44M |
|
1489
Tactile Systems Technology
TCMD
$534M
| $1.43M | ﹤0.01% |
71,130
-26,620
| -27% | -$465K |
|
1490
Recursion Pharmaceuticals
RXRX
$1.91B
| $1.43M | ﹤0.01% |
+200,131
| New | +$2.13M |
|
|
NPTN
1491
DELISTED
NEOPHOTONICS CORP
NPTN
| $1.43M | ﹤0.01% |
93,907
-292,213
| -76% | -$4.45M |
|
|
NTP
1492
DELISTED
Nam Tai Property Inc.
NTP
| $1.43M | ﹤0.01% |
228,542
-3,191
| -1% | -$26.3K |
|
1493
Theravance Biopharma
TBPH
$884M
| $1.43M | ﹤0.01% |
149,240
+114,174
| +326% | +$1.12M |
|
1494
Integer Holdings
ITGR
$4.26B
| $1.43M | ﹤0.01% |
17,699
-45,706
| -72% | -$3.69M |
|
1495
Community Trust Bancorp
CTBI
$1.39B
| $1.42M | ﹤0.01% |
34,532
+3,713
| +12% | +$161K |
|
1496
Financial Institutions
FISI
$800M
| $1.42M | ﹤0.01% |
47,191
+12,326
| +35% | +$396K |
|
|
CLVS
1497
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.42M | ﹤0.01% |
+703,171
| New | +$1.38M |
|
1498
Saratoga Investment
SAR
$296M
| $1.42M | ﹤0.01% |
51,897
-32,741
| -39% | -$900K |
|
|
NAPA
1499
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $1.42M | ﹤0.01% |
77,791
-107,901
| -58% | -$2.11M |
|
1500
XWELL
XWEL
$8.68M
| $1.41M | ﹤0.01% |
62,561
-31,831
| -34% | -$852K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.